Hong Kong suspended the sale of the painkiller Bextra on Friday one day after the drug was pulled off U.S. shelves because it has been linked to increased risk of heart attacks and a rare skin condition.
Patients should “stop taking Bextra and contact their physicians about appropriate treatment options,” Hong Kong’s Health Department said in a news release.
The drug’s importer, Pfizer Corporation Hong Kong Ltd., has agreed to immediately stop selling the prescription medication, the department said.
Pfizer Inc. (PFE) suspended sales of Bextra in the U.S. on Thursday at the request of the U.S. Food and Drug Administration. The company said that the FDA cited a risk of serious skin reactions to Bextra.